Prifemilast Reaches PASI 75 in 57.4% at Week 16 in Phase 3
Randomized phase 3 data showed PASI 75 rates of 51.8% with prifemilast 10 mg and 57.4% with 20 mg at week 16, versus 10.8% with placebo in a 505-adult trial.
Topic
Pde4b Inhibitor
Topic
Topic
Topic
Randomized phase 3 data showed PASI 75 rates of 51.8% with prifemilast 10 mg and 57.4% with 20 mg at week 16, versus 10.8% with placebo in a 505-adult trial.